After six weeks, both the treatment group and the placebo group experienced an average 12.5-point reduction on the Montgomery-Åsberg Depression Rating Scale (MADRS). The drug also fell short in i ...
Resources used to select the drug name pairs targeted for tall man letters included the ISMP list of name pairs with recommended tall man letters (63%), the FDA-approved list of name pairs with ...
The study failed to achieve its primary endpoint – treatment with the drug failed to demonstrate a significant improvement over placebo in alleviating depression symptoms, as measured by the ...
(NASDAQ: NMRA) nosedived by more than 80 percent during pre-market trading following disappointing results from the Phase 3 trial of navacaprant, a drug being developed to treat major depressive ...
s shares plummeted the most on record after the company’s experimental drug for the treatment of ... significant improvement in a measurement of depression symptoms, the company said Thursday.
Neumora Therapeutics said on Thursday its experimental drug to treat depression failed to meet the main goal of a late-stage study, sending shares of the company down 82% in premarket trading. The ...